RESEARCH ARTICLE

REVISED Anti-Mullerian hormone levels in female cancer patients of reproductive age in Indonesia: A cross-sectional study [version 2; peer review: 1 approved, 1 approved with reservations]

Achmad Kemal Harzif¹, Budi Wiweko¹, Putri Addina², Kartika Iswaranti², Melisa Silvia³, Ana Mariana³, Kresna Mutia³, Kanadi Sumapraja¹, R Muharam¹, Gita Pratama¹

¹Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, DKI Jakarta Province, Indonesia

²Department of Obstetrics and Gynecology Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, DKI Jakarta Province, Indonesia

³Indonesian Reproductive Medicine Research and Training Center (INA-REPMED) of Faculty of Medicine Universitas Indonesia,, Dr. Cipto Mangunkusumo Hospital, Jakarta, DKI Jakarta Province, Indonesia

V2 First published: 06 Feb 2019, 8:159
<https://doi.org/10.12688/f1000research.15728.1>
 Second version: 12 Jul 2019, 8:159
<https://doi.org/10.12688/f1000research.15728.2>
 Latest published: 20 Feb 2020, 8:159
<https://doi.org/10.12688/f1000research.15728.3>

Abstract

Background: Efforts in reproductive preservation for cancer patients have become one of the important aspects of cancer management. In fact, decline in reproductive function is known to occur after exposure to anti-cancer treatments. Measuring anti-Müllerian hormone (AMH) levels is known to be the best parameter in predicting ovarian reserves, which indicates reproductive function. In total, 68% of cancer survivors of reproductive age who underwent anti-cancer treatments suffer from infertility. Meanwhile, ovarian reserves also decrease with increasing age. There is ongoing debate on whether the ovarian reserves of cancer patients could be reduced long before exposure to anti-cancer therapy. Therefore, it is important to know whether ovarian reserves in cancer patients decrease before or after anti-cancer therapy. This can help predict the reproductive function in such cases and the effectiveness of ovarian preservation efforts.

Methods: A cross-sectional study was conducted, comparing the AMH levels of 44 female cancer patients of reproductive age before cancer therapy, to 44 non-cancer patients of reproductive age (age matched). The biological ages from both groups were adjusted using the Indonesian Kalkulator of Oocytes.

Results: The median age in both groups was 28 years old. The AMH

Open Peer Review

Approval Status

	1	2
version 3 (revision) 20 Feb 2020		view
version 2 (revision) 12 Jul 2019	view	view
version 1 06 Feb 2019	view	

1. Nao Suzuki¹, St. Marianna University School of Medicine, Kawasaki, Japan
2. Xiang-Xi (Mike) Xu, University of Miami, Miami, USA

Any reports and responses or comments on the article can be found at the end of the article.

levels in the cancer group were found to be significantly lower in contrast to those in the non-cancer group (1.11 [0.08-4.65] ng/ml vs. 3.99 [1.19- 8.7]; p- value <0.001). Therefore, the biological age in the cancer group was 10 years older than that of the non-cancer group, indicating that ovarian aging occurs earlier in cancer patients.

Conclusions: AMH levels of cancer patients of reproductive age were already reduced before cancer therapy, given an older biological age, in contrast to that of the non-cancer patients. Proper counseling and implementation of fertility-preserving methods is highly recommended in this group of patients.

Keywords

Anti Mullerian Hormone (AMH), Ovarian Reserve, Cancer in Reproductive, Biological Age

This article is included in the **Oncology** gateway.

Corresponding author: Budi Wiweko (budiwiweko@gmail.com)

Author roles: Harzif AK: Conceptualization, Project Administration, Supervision, Writing – Review & Editing; Wiweko B: Conceptualization, Project Administration, Supervision, Writing – Review & Editing; Addina P: Data Curation, Investigation, Methodology, Resources, Validation, Visualization, Writing – Original Draft Preparation; Iswaranti K: Investigation, Methodology, Resources, Software, Visualization; Silvia M: Investigation, Methodology, Resources, Software, Visualization; Mariana A: Writing – Review & Editing; Mutia K: Investigation, Methodology, Resources, Validation, Visualization; Sumapraja K: Supervision, Writing – Review & Editing; Muharam R: Supervision, Writing – Review & Editing; Pratama G: Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work is supported by Hibah PITTA 2018 funded by DRPM Universitas Indonesia No.5000/UN2.R3.1/HKP.05.00/2018

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Harzif AK *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Harzif AK, Wiweko B, Addina P *et al.* **Anti-Mullerian hormone levels in female cancer patients of reproductive age in Indonesia: A cross-sectional study [version 2; peer review: 1 approved, 1 approved with reservations]** F1000Research 2019, 8:159 <https://doi.org/10.12688/f1000research.15728.2>

First published: 06 Feb 2019, 8:159 <https://doi.org/10.12688/f1000research.15728.1>

REVISED Amendments from Version 1

In response to the reviewer, a statement which read “....(AMH) level is known to be the best parameter...” has been changed to read “....(AMH) level is known to be one of the best parameters...”

We have added the information for the inclusion and exclusion criteria. For inclusion, we have added “....(c) Non-cancer patients who never had a history of chemotherapy/radiation. No prior pregnancy or infertility treatment for the non-cancer group...” and for exclusion, we have added, “.....(c) former cancer patient.”

We have extended our opinions and citations about the racial differences and the reasons why ovarian aging occurs earlier in cancer patients. The information has been added in the Discussion section.

See referee reports

Introduction

Reproductive preservation efforts for cancer patients have become an important aspect of cancer management. Of all female cancer cases worldwide, 10% of cases occur during reproductive age¹. Most cancer patients do not have an opportunity to preserve reproductive function prior to cancer treatment, and decline in reproductive function is known to occur after exposure to cancer treatments, whether it be chemotherapy or radiotherapy. In total, 68% of cancer survivors of reproductive age who have undergone anti-cancer treatments experience infertility, amenorrhea, reduction of ovarian reserves, and premature ovarian failure. Ovarian reserves also decrease with increasing age^{2,3}, therefore, the American Society of Clinical Oncology (ASCO), and the American Society for Reproductive Medicine (ASRM) have recommended that consultation on fertility preservation methods prior to cancer therapy should be provided⁴. However, there is an ongoing debate on whether the ovarian reserves of cancer patients could be reduced long before exposure to anti-cancer therapy.

The measurement of the anti-Müllerian hormone (AMH) levels is known to be the best parameter for predicting ovarian reserves, which represent reproductive function⁵. Low AMH levels reflect a low ovarian reserve^{6,7}.

Several studies have shown that in breast cancer and lymphoma patients, ovarian reserves are already decreased prior to cancer therapy. However, other studies have shown that a decreased ovarian reserve is only associated with increasing age. It is, therefore, important to know whether the ovarian reserves in cancer patients decrease before or after therapy. This will help predict the reproductive function in such cases and the effectiveness of ovarian preservation efforts.

Methods

Study design and patient population

This is a cross-sectional study that compares the AMH levels of reproductive age cancer patients before cancer treatment with non-cancer patients. We enrolled 88 subjects; 44 cancer patients of reproductive age before cancer treatment and 44 non-cancer patients (similar age). For cancer group data, patients were recruited from three places; Obstetrics and Gynecology

Polyclinics, Hematology Oncology Polyclinics of Cipto Mangunkusumo Hospital, Obstetrics and Gynecology Polyclinics and Inpatient Unit of Dharmas Cancer Hospital, from May 2015 to December 2017. For non-cancer group data, AMH levels were obtained as secondary data from our previous study⁸, from which we selected patients with a similar age as patients in the cancer group. Inclusion criteria for this study were (a) Cancer and non-cancer patients aged 17–40 years, (b) Cancer patients who have never had a history of cancer therapy: chemotherapy/radiation, de-bulking tumors (specifically gynecology), (c) Non-cancer patients who never had a history of chemotherapy/radiation. No prior pregnancy or infertility treatment for the non-cancer group; and exclusion criteria were (a) respondents who not willing to be a participant in this study, (b) incomplete of filling informed consent and (c) former cancer patient. The sample size was derived from the formula $n = \frac{Z^2 pq}{d^2}$ where n is the minimum sample size, Z is the standard normal deviation, as in majority of studies p values are considered significant below 0.05 hence 1.96 is used in formula, p is expected proportion in population based on previous studies (0.36), q is 1-p (0.64), d is the absolute error or precision (0.1 or 10%). Therefore, the total sample size for this study was calculated to be 88 sample subjects and the comparison of cancer groups before cancer therapy and non cancer group was 1:1 meaning the total sample size for each group was 44 subjects. Unpaired numerical analysis formulas were used to compare AMH levels between cancer patients in reproductive age before cancer therapy with non-cancer patients. The standard deviation for each group are calculated separately, and result shows S1 was standard deviation of the cancer group by: 1,088 ng/dl (mean 1.4 ng/dl) and S2 was standard deviation of non-cancer group by : 2.20 ng/dl (mean 4.37 ng/dl). For calculate the minimum number of samples that can be used in this study, and also know the effect size and power of the study so all collected data were inputted to **G Power software** version 3.0.10. As a result, minimum sample subject count for each group of at least 7 subjects, with actual P 0.83.

Data collection

Data collection was performed by consecutive sampling. In cancer group participants, they were given an explanation of the purpose and benefits of the study, and as asked to provide written consent to participate in the study. The written approval sheet was signed by the patient and the researcher. Researchers registered cases and filled out research status forms (**Supplementary File 1** and **Supplementary File 2**). Blood serum (3 ml) from the cubital vein was collected from the cancer group, and stored in vacutainer without anticoagulants. This serum then sent to FKUI Integrated Laboratory for AMH measurement using ELISA techniques by AMH GEN II ELISA Beckman Coulter REF A79765 (with VMax machines). ELISA was performed to the manufacturer's protocol. After obtaining the results of AMH levels, data analysis was performed. Full method for AMH hormone examination for cancer groups were taken 3 ml of venous blood from the cubital vein of the media and stored in a vacutainer without anticoagulants. After liquefaction and at room temperature, the AMH examination was carried out manually with a micro ELISA technique read with a VMAX type kinetic microplate reader with **Softmax Pro Software** version 5.4.1.

Statistical analysis

Statistical analyses were performed using IBM SPSS version 20. Data on ovarian reserves expressed in AMH levels from the cancer patients and the non-cancer patients are presented as medians (minimum-maximum) because the data were not normally distributed. Mann-Whitney tests were performed to compare the differences in ovarian reserves (AMH levels) between the cancer group and the non-cancer group.

Ethical approval

The Ethics Committee of the Faculty of Medicine from Universitas Indonesia approved this study on May 5, 2015 (*reference number: 286/UN2.F1/ATIK/2015*). All prospective subjects received an explanation from the main researcher and additional researchers regarding the procedures for conducting research. The decision to follow or refuse to follow the research was taken by informed consent. All data will be kept confidential and the subject had the right to know all the results of the examination carried out.

Results

The 88 subjects participated in this study, with similar characteristics between the two arms. The mean age for cancer and non-cancer groups was the same, 28 years. For the cancer patient menarche age was 11 years. Body mass index for cancer patients was 20.7 ± 3.89 , and non-cancer patients 19.5 ± 2.561 . Both groups have the same parity average of 0. The mean AMH level for cancer patients was 1.11 ng/ml (0.08–4.65 ng/ml), and for non-cancer patients 3.99 ng/ml (1.19–8.7 ng/ml). The biological age for cancer patients based on an AMH level of 1.1 ng/ml was 38 years old, and for non-cancer patients 3.99 ng/ml corresponded to 28 years old. Characteristics of research subjects can be seen in Table 1. Of all the cancer patients recruited in the study, 14 subjects were gynecologic cancer patients and 30 subjects were non-gynecologic cancer patients, the distribution of cancer cases can be seen in Table 2.

Overall, the AMH levels were abnormally distributed (Kolmogorov-Smirnov test for normality, p -value <0.001) with

Table 1. Baseline characteristics.

Characteristic	Cancer group N: 44	Non-cancer group N: 44	<i>p</i> -value
Age, years (min-max)	28 (18–37)	28.5(22–37)	0.364
Menarche, age in years (min-max)	11 (8–13)	11 (8–13)	0.364
BMI, kg (SD)	$20,7 \pm 3.89$	$19,5 \pm 2.561$	0.043
Parity, n (min-max)	0 (0–2)	0 (0–3)	0.449
AMH, ng/dl (min-max)	1.11 (0.08–4.65)	3.99 (1.19–8.7)	<0.001
Biological age* (min-max)	38	28	-

Notes: *Biological age based on AMH level is in accordance with the Indonesian Calculator of Oocyte. BMI: Body mass index, AMH: Anti-Mullerian hormone

Table 2. Cancer distribution.

Cancer type	(n)
Gynecologic cancer	14
Cervical cancer	7
Ovarian cancer	5
Endometrial cancer	1
Vaginal cancer	1
Non-gynecologic cancer	30
Breast cancer	9
Non-Hodgkin Lymphoma	7
Acute myelogenous leukemia	1
Chronic myelogenous leukemia	4
Acute Lymphocytic Leukemia	2
Rectal cancer	
Tongue cancer	1
Myelodysplastic syndromes	1
Nasopharyngeal cancer	1
Vesical cancer	1
Adenocystic carcinoma	1

a median level of AMH 2.06 ng/ml (0.08–8.78 ng/ml). AMH levels in the cancer group were lower than that of the non-cancer group (1.11 [0.08–4.65] ng/ml vs. 3.99 [1.19–8.7]; p-value <0.001). This study also showed that there were no statistically significant differences between the AMH levels of the gynecologic cancer patients 0.965 ng/ml (0.08–2.65 ng/ml) and the non-gynecological cancer patients before treatments 1.49 ng/ml (0.08–4.65 ng/ml); p-value 0.162.

Dataset 1. All raw data and demographic information obtained from subject during the present study

<http://dx.doi.org/10.5256/f1000research.15728.d229186>

Discussion

In line with advances in cancer therapy, the survival rate of cancer patients also increases. Unfortunately, this rate of improvement does not coincide with an increased quality of life, especially in regards to reproductive function. Currently, one of the best parameter to measure ovarian reserves is by measuring serum AMH levels; AMH levels can also help predict biological age, which is of more importance when assessing reproductive function.

There are several types of cancer known to be associated with decreased ovarian reserves prior to cancer therapy, such as Hodgkin and Non-Hodgkin's lymphoma, and breast cancer. Lawrenz *et al.* demonstrated that the AMH levels of lymphoma patients were lower than that in non-cancer patients, with mean AMH levels of 2.06 ng/ml vs. 3.20 ng/dl (p-value <0.05)⁹. Su *et al.* conducted a similar study wherein the AMH levels of the breast cancer patients were lower than that of the non-cancer patients, 0.6 ng/ml vs. 1.1 ng/ml (p-value <0.001)¹⁰. Van *et al.* also conducted a broader study in 2014 comparing the AMH levels in young cancer patients (<18 years) before treatment with non-cancer patients (age-matched). The results showed that AMH levels in the cancer group were significantly lower than that of the non-cancer group, 1.4 mg/l vs. 3.0 mg/l (p-value <0.001)¹¹. The results of these three studies were similar to that of our study; the AMH levels of the 44 reproductive age cancer patients prior to cancer treatment were lower than that of the non-cancer patients (1.11 [0.08–4.65] ng/ml vs. 3.99 [1.19–8.7] ng/ml; p-value <0.001).

Although some studies have shown that the ovarian reserves of reproductive-age cancer patients before treatment are lower than that of the non-cancer patients, the factors that directly affect AMH levels are still unknown. Several studies have suggested genetic mutations, such as BRCA gene mutations, may affect ovarian reserves in breast cancer patients^{12–14}; the effects of high cytokines in lymphoma patients indirectly affect the ovarian reserves as well^{15,16}. In non-cancer populations, Jung *et al.* has proven that only the age of menarche affected the concentration of AMH (age of menarche <12 years vs. ≥14 years, 0.90 ng/mL vs. 1.12 ng/mL), while ethnicity, BMI, education level, smoking status, height, and menstrual cycle are not associated with AMH concentrations. There was no significant variations in AMH concentrations between Asian women and white women (age-adjusted

model ; p < 0.77, multivariable model ; p < 0.62)¹⁷. Bleil *et al.* found there was a statistically significant race/ethnicity-by-linear age interaction among healthy and regularly cycling women, indicating that differences in AMH levels between race/ethnic groups varied as a function of age¹⁸. Su *et al.* found that age, BMI, parity, and smoking status are not associated with decreased levels of AMH in patients with breast cancer¹⁰. The differences result between previous studies may arise from the varying environment conditions, and heterogeneous character of the populations studied. Serum AMH levels may be influenced by genetic and environmental factors. Our study found that the decreasing level of AMH in cancer group before therapy was related to older of biological age. The result of biological age from both groups were adjusted by Indonesian Kalkulator of Oocytes (IKO) and referred to previous study from Wiweko *et al.* among Indonesian women who went through AMH level test. By using data from this study as reference, we could exclude racial differences of AMH¹⁹.

In contrast to other types of non-gynecological cancers, reproductive preservation in gynecological cancers is not widely discussed. This is related to the fact that the genital organs themselves are involved in the cancer and the local treatments of such cancers are destructive to the organs of reproduction²⁰. Therefore, in this study, we compared the AMH levels of gynecologic patients of reproductive age before receiving cancer treatment with the non-gynecological cancer patients, and we found no significant difference between AMH levels (0.965 ng/dl vs. 1.49 ng/dl; p-value 0.162). However, the unequal size of the gynecological and non-gynecological cancers subject groups in our study may have affected the results. With increasing age the capability of a woman to produce appropriate quality oocytes, and quantity of oocytes decreases; this process, called ovarian aging, is defined as a gradual decrease in both the quantity and quality of the oocytes. The decrease in the quality and quantity of these oocytes is related to chronological age and biological age²¹. Chronological age is determined by the passage of time from birth, while the biological age is determined by physiology²². Biological age affects the reproductive function more than chronological age, besides that ovarian reserve is a good marker for representing the biological age of the ovary. In this study, the biological age of the cancer group was 10 years higher than that of the non-cancer group, indicating that ovarian aging occurs earlier in cancer patients. This would indicate that reproductive preservation methods should be offered long before cancer patients undergo therapy.

There is a hypothesis that reported a decreased number of ovarian follicles and an increased gonadotropin level which caused an inflammatory environment and changing epithelial cell surface and the development of tumors in the ovary²³. Other studies have suggested genetic mutations were associated with ovarian aging. Johnson *et al.* observed BRCA2 carriers had significantly lower AMH levels compared to healthy, low-risk women and had increased odds of having a low AMH (OR 3.69, 95% 1.34–10.19, p=0.012). BRCA 2 as tumor suppressor genes which involved in the regulation of follicular pool through impairment of DNA repair pathway and affected ovarian reserves in breast cancer patients²⁴. A study in lymphoma

patients showed significantly lower AMH levels than in the control group. There is a strong negative correlation between AMH with SIL-2R, IL-6, and IL-8 cytokines exists¹⁵. The impairment of DNA repair mechanisms may affect the granulosa cell function. This condition cause AMH decreased independently in childhood cancer¹¹.

There are many reproductive preservation techniques; however, one of technique for cancer patients is ovarian cryopreservation. This technique consists of two methods: the slow cooling method and vitrification ovary. Based on the research conducted by Wiweko *et al.*, ovarian vitrification techniques are superior to the slow cooling method²⁵. Ovarian vitrification does not alter the morphology of the granulosa cells, or the stromal and ovarian collagen components¹⁹. It has also been shown to not change the morphology of the pre-antral follicle nor does it increase the risk of cell apoptosis^{19,25}. Other options that may still be offered to cancer patients of reproductive age are oocyte cryopreservation and embryo cryopreservation. In patients who already have a partner or are married, embryo cryopreservation can be offered, however, this may delay cancer therapy due to the ovarian stimulation process required for this technique. In addition to this, estrogen exposure given at the time of ovarian stimulation may have an adverse effect in estrogen sensitive tumors. Unlike embryo cryopreservation, cryopreservation of the oocytes can be used for single women who can undergo the stimulation cycle, but the effectiveness of this technique is very low. The pregnancy and delivery rates range from 1 to 5% per frozen oocyte²⁶. The current weakness of this study is that the other gynecological abnormalities that may affect AMH levels in both groups were not included in the screening criteria for exclusion, such as genetic factors and the type/stage of cancer or other diseases which may affect the levels of AMH, were also not studied.

Conclusions

This study showed that the AMH levels in reproductive age patients before receiving therapy were lower in contrast to that in the non-cancer patients (1.11 ng/ml vs. 3.99 ng/ml; p- value <0.001). In addition to this, there was no significant difference in the AMH levels between the gynecologic and non-gynecologic cancer groups before treatment (0.965 ng/dl vs. 1.49 ng/dl; p- value 0.162).

Data availability

F1000Research: Dataset 1. All raw data and demographic information obtained from subject during the present study, <https://doi.org/10.5256/f1000research.15728.d229186>²⁷.

Grant information

This work is supported by Hibah PITTA 2018 funded by DRPM Universitas Indonesia No.5000/UN2.R3.1/HKP.05.00/2018.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

The authors wish to thank all the staff members from INA-REPROD, Polyclinic Obstetrics and Gynecology, Division of Hemato-oncology Department of Internal Faculty of Medicine Universitas Indonesia, Departement of Internal Medicine and all the staff members from Kanker Dharmas Hospital, Jakarta. We also would like to thank to the professional copyedited by Editage for helping us improve our manuscript by copyedited and given us a thoughtful comments in this manuscript as well.

Supplementary material

Supplementary File 1: Questionnaire and informed consent form in Bahasa Indonesia.

[Click here to access the data.](#)

Supplementary File 2: Questionnaire and informed consent form in English.

[Click here to access the data.](#)

References

- Patel AA, Mini S, Sutaria RP, *et al.*: **Reproductive health issues in women with cancer.** *J Oncol Pract.* 2008; 4(2): 101–105.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Meirow D, Nugent D: **The effects of radiotherapy and chemotherapy on female reproduction.** *Hum Reprod Update.* 2001; 7(6): 535–543.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Oktem O: **Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function.** *Cancer.* 2007; 110(10): 2222–2229.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Das M, Shehata F, Moria A, *et al.*: **Ovarian reserve, response to gonadotropins, and oocyte maturity in women with malignancy.** *Fertil Steril.* 2011; 96(1): 122–125.
[PubMed Abstract](#) | [Publisher Full Text](#)

5. Lie Fong S, Laven JS, Hakvoort-Cammel FG, *et al.*: **Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone.** *Hum Reprod.* 2009; **24**(4): 982–990.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Anderson RA, Wallace WH: **Antimüllerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer.** *Fertil Steril.* 2013; **99**(6): 1469–1475.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. van Rooij IA, Broekmans FJ, te Velde ER, *et al.*: **Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve.** *Hum Reprod.* 2002; **17**(12): 3065–3071.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Wiweko B, Prawesti DM, Hestiantoro A, *et al.*: **Chronological age vs biological age: an age-related normogram for antral follicle count, FSH and anti-Müllerian hormone.** *J Assist Reprod Genet.* 2013; **30**(12): 1563–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Lawrenz B, Fehm T, von Wolff M, *et al.*: **Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma—Evaluation by using antimüllerian hormone and retrieved oocytes.** *Fertil Steril.* 2012; **98**(1): 141–144.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Su H, Flatt SW, Natarajan L, *et al.*: **Impact of breast cancer on anti-müllerian hormone levels in young women.** *Breast Cancer Res Treat.* 2013; **137**(2): 571–577.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. van Dorp W, van den Heuvel-Eibrink MM, de Vries AC, *et al.*: **Decreased serum anti-Müllerian hormone levels in girls with newly diagnosed cancer.** *Hum Reprod.* 2014; **29**(2): 337–342.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Giordano S, Garrett-Mayer E, Mittal N, *et al.*: **Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk.** *J Adolesc Young Adult Oncol.* 2016; **5**(4): 337–343.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Lansdorp PM: **Repair of telomeric DNA prior to replicative senescence.** *Mech Ageing Dev.* 2000; **118**(1–2): 23–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. McPherson JP, Hande MP, Poonepalli A, *et al.*: **A role for Brca1 in chromosome end maintenance.** *Hum Mol Genet.* 2006; **15**(6): 831–838.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Paradisi R, Vicenti R, Macciocia M, *et al.*: **High cytokine expression and reduced ovarian reserve in patients with Hodgkin lymphoma or non-Hodgkin lymphoma.** *Fertil Steril.* 2016; **106**(5): 1176–1182.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Fabbri R, Pasquinelli G, Magnani V, *et al.*: **Follicle features in adolescent and young adult women with Hodgkin's disease prior to chemotherapy: a preliminary report.** *Reprod Biomed Online.* 2011; **23**(6): 799–805.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Jung S, Allen N, Arslan AA, *et al.*: **Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women.** *Fertil Steril.* 2017; **107**(4): 1012–1022.e2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Bleil ME, Gregorich SE, Adler NE, *et al.*: **Race/ethnic disparities in reproductive age: an examination of ovarian reserve estimates across four race/ethnic groups of healthy, regularly cycling women.** *Fertil Steril.* 2014; **101**(1): 199–207.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Wiweko B, Maidarti M, Mansyur E, *et al.*: **Ovarian tissue vitrification as a method for fertility preservation: A study of follicle number and morphology after vitrification.** *IVF Lite.* 2014; **1**(3): 148–152.
[Publisher Full Text](#)
20. Aubard Y, Piver P, Pech JC, *et al.*: **Ovarian tissue cryopreservation and gynecologic oncology: a review.** *Eur J Obstet Gynecol Reprod Biol.* 2001; **97**(1): 5–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Alviggi C, Humaidan P, Howles CM, *et al.*: **Biological versus chronological ovarian age: Implications for assisted reproductive technology.** *Reprod Biol Endocrinol.* 2009; **7**: 101.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Broekmans FJ, Kwee J, Hendriks DJ, *et al.*: **A systematic review of tests predicting ovarian reserve and IVF outcome.** *Hum Reprod Update.* 2006; **12**(6): 685–718.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Smith ER, Xu XX: **Ovarian ageing, follicle depletion, and cancer: a hypothesis for the aetiology of epithelial ovarian cancer involving follicle depletion.** *Lancet Oncol.* 2008; **9**(11): 1108–1111.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Johnson L, Sammel MD, Domchek S, *et al.*: **Antimüllerian hormone levels are lower in BRCA2 mutation carriers.** *Fertil Steril.* 2017; **107**(5): 1256–1265.e6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Wiweko B, Andriyana H, Aulia A: **Ovarian Tissue Vitrification as a Method for Ovarian Preservation in Women with Cancer: an Analysis of Granulosa Cell Apoptosis.** *Indonesian J Obstet Gynecol.* 2016; **4**(2): 88–92.
[Publisher Full Text](#)
26. Chang HJ, Suh CS: **Fertility preservation for women with malignancies: current developments of cryopreservation.** *J Gynecol Oncol.* 2008; **19**(2): 99–107.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Harzif AK, Wiweko B, Addina P, *et al.*: **Dataset 1 in: Anti-Müllerian hormone levels in female cancer patients of reproductive age in Indonesia: A cross-sectional study.** *F1000Research.* 2018.
<http://www.doi.org/10.5256s/f1000research.15728.d229186>

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 02 October 2019

<https://doi.org/10.5256/f1000research.21664.r54585>

© 2019 Xu X. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Xiang-Xi (Mike) Xu

Sylvester Cancer Center (SCCC), Ovarian Cancer Program, University of Miami, Miami, FL, USA

The study is interesting and the conclusion is provocative: AMH is 1.11 in cancer and 3.99 in non-cancer. However, there are several red flags and suggestions need to be considered:

1. It should be mentioned that AMH was determined from blood, in Abstract and Results.
2. If the authors have sufficient background, it should be discussed about the biology and AMH production by ovarian follicles.
3. The number of patients is not very big. It would be more informative to see a dot plot where every patient represents one dot.
4. The Age of the patients (28, 18-37) is something of a red flag. For ovarian epithelial cancer, 95% of the cases are 55 or older.
5. Doubtfully, all cancer types are affected by AMH. The gynec cancer (14 cases) should be also analysed separately.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

No

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 08 Jan 2020

Achmad Kemal

Dear Xiang-Xi,

Thank you for the review. We have uploaded the revision of our manuscript regarding to your suggestion.

1. It should be mentioned that AMH was determined from blood, in Abstract and Results.

Yes, we agree with your suggestion to mentioned that AMH was determined from blood. The change has been made.

2. If the authors have sufficient background, it should be discussed about the biology and AMH production by ovarian follicles.

We have added some references about AMH production

3. The number of patients is not very big. It would be more informative to see a dot plot where every patient represents one dot.

The dot plot of age, biological age, menarche, parity, and AMH in all subjects can be seen in Figure 1.

4. The Age of the patients (28, 18-37) is something of a red flag. For ovarian epithelial cancer, 95% of the cases are 55 or older.

In this study, we collected samples between 17 and 40 yr to measure the level of AMH that correlated with reproductive age and compared their biological and chronological age. We have found a significant result that female cancer patients are highly potential to have ovarian aging earlier than non-cancer patients .

5. Doubtfully, all cancer types are affected by AMH. The gynec cancer (14 cases) should be also analysed separately.

We found that there is not a significant value for the level of AMH between our ovarian cancer group and the non-ovarian cancer group (0.947). These data may be biased because of the unequal size. Numerous samples are needed to obtain a valid result.

We carefully have modified the manuscript according to your instructions. Thank you for your considerations, we looking forward to any helpful feedback.

Best Regards,
Achmad Kemal

Competing Interests: No competing interests were disclosed.

Author Response 27 Jan 2020

Achmad Kemal

Dear Mike Xu,

We hope that you can give us further feedback and evaluation according to your queries

Achmad Kemal Harzif

Competing Interests: No competing interests were disclosed.

Reviewer Report 22 July 2019

<https://doi.org/10.5256/f1000research.21664.r51171>

© 2019 Suzuki N. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nao Suzuki

Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan

I think the author's revisions are sufficient for me to amend the status of 'approved with reservations'.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 10 June 2019

<https://doi.org/10.5256/f1000research.17166.r48874>

© 2019 Suzuki N. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nao Suzuki

¹ Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan

² Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan

This is a well-written manuscript about Anti-Mullerian hormone levels in female cancer patients of reproductive age in Indonesia. The aim of the study is to predict the reproductive function of cancer patients. The major limitation of the study is a low number of participants in two groups. I have a few other comments for the authors.

- Page 3 left panel L 21: I think the AMH levels are known to be one of the best parameters for predicting ovarian reserves. I do not think this is the best parameter. I need the author's opinions.
- Page 3 left panel L 43: Please add the information about the past history of pregnancy and birth, and infertility treatment in the non-cancer group.
- Whether there is racial difference? Please add the author's opinions in the discussion.
- Please add more precise opinions regarding the reasons why ovarian aging occurs earlier in cancer patients.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

No

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Fertility preservation for the young cancer patients, oncology.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 19 Jun 2019

Achmad Kemal

We are grateful for the helpful feedback by the reviewer that helped us improve the quality of our manuscript. We carefully responded to all points and have modified the manuscript accordingly. Please see below our detailed response to comments.

Page 3 left panel L 21: I think the AMH levels are known to be one of the best parameters for predicting ovarian reserves. I do not think this is the best parameter. I need the author's opinions.

Answer: Yes, we agree that AMH level is one of the best parameters for predicting ovarian reserves. The correction has been made in the manuscript

Page 3 left panel L 43: Please add the information about the past history of pregnancy and birth, and infertility treatment in the non-cancer group.

Answer:

We have added the information for the inclusion and exclusion criteria. The highlighted sentences are the additional information. "...Inclusion criteria for this study were (a) Cancer and non-cancer patients aged 17–40 years (b) Cancer patients who have never had a history of cancer therapy: chemotherapy/radiation, de-bulking tumors (specifically gynecology) (c) **Non-cancer patients who never had a history of chemotherapy/radiation. No prior**

pregnancy or infertility treatment for the non-cancer group; and exclusion criteria were (a) respondents who not willing to be a participant in this study (b) incomplete of filling informed consent and (c) former cancer patient.

The informations have been added to the manuscript.

Whether there is racial difference? Please add the author's opinions in the discussion

Answer:

We thank the reviewer for this comment. As explained in Page 5 left panel L 45, Jung et al found that there was no significant variations in AMH concentrations between Asian women and white women (age-adjusted model ; $p < 0.77$, multivariable model ; $p < 0.62$). Although, Bleil et al. found there was a statistically significant race/ethnicity-by-linear age interaction among healthy and regularly cycling women, indicating that differences in AMH levels between race/ethnic groups varied as a function of age. The differences result between previous studies may arise from the varying environment conditions, and heterogeneous character of the populations studied. Serum AMH levels may be influenced by genetic and environmental factors.

Our study found that the decreasing level of AMH in cancer group before therapy was related to older of biological age. The result of biological age from both groups were adjusted by Indonesian Kalkulator of Oocytes (IKO) and referred to previous study from Wiweko et al among Indonesian women who went through AMH level test. By using data from this study as reference, we could exclude racial differences of AMH. Our opinions have been added in the discussion of this manuscript.

Please add more precise opinions regarding the reasons why ovarian aging occurs earlier in cancer patients.

Answer:

There is a hypothesis that reported a decreased number of ovarian follicles and an increased gonadotropin level which caused an inflammatory environment and changing epithelial cell surface and the development of tumors in the ovary. Other studies have suggested genetic mutations were associated with ovarian aging. Johnson et al observed BRCA2 carriers had significantly lower AMH levels compared to healthy, low-risk women and had increased odds of having a low AMH (OR 3.69, 95% 1.34–10.19, $p=0.012$). BRCA 2 as tumor suppressor genes which involved in the regulation of follicular pool through impairment of DNA repair pathway and affected ovarian reserves in breast cancer patients. A study in lymphoma patients showed significantly lower AMH levels than in the control group. There is a strong negative correlation between AMH with SIL-2R, IL-6, and IL-8 cytokines exists. Van Dorp et al found that a significantly lower serum AMH levels of girls with childhood cancer compared with healthy age-matched controls (standard deviation scores (SDS) 20.8, $p<0.001$). Potential cause of the decreased AMH independently of childhood cancer subtype might be impaired granulosa cell function due to an impaired DNA repair mechanism.

Our opinions have been added to the manuscript. We carefully have modified the manuscript according to the editor instructions. Thank you for your considerations, we looking forward to any helpful feedback.

Best Regards,
Achmad Kemal

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research